HIV/AIDS Treatment Trends and Progress: Where Do We Stand Today?
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Address: PO Box 781247
Sandton 2146
Gauteng,South Africa
Tel: +27 11 883 5630
Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout our long history, we have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. We are committed to developing products not only to treat life-threatening conditions, but importantly, to improve the quality of life for patients with a variety of acute and chronic illnesses. We have a long-standing tradition of building high quality relationships based on the highest standards, with patients, physicians, employees, partners and other key stakeholders.
In the last fifteen years, we have focused on expanding our pan-European infrastructure, and have moved to strengthen the Research & Development base of the company.
In addition to developing, manufacturing and marketing our own pharmaceutical products, Norgine is an ideal partner for companies seeking assistance in the development and commercialisation of innovative pharmaceutical products across Europe. We value our development partnerships as, together with our own in-house product development, they support our growth ambitions and will help to facilitate our continued business expansion.
We have the resources to bring products to market on a pan-European or single country basis by combining sales and marketing expertise with all development, clinical research, product registration or manufacturing resources that our partners require.
In the years ahead, Norgine will continue to implement this successful strategy, building on our established infrastructure, strengthening our pan-European presence and collaborating with like-minded companies and organisations. By consolidating our successes, we can ensure we meet the challenges of an exciting future.
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential…
The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one…
In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of…
During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in…
As part of a special focus on drug development and clinical research in Africa in February 2023’s DIA Global Forum magazine, Lisa Ursella Collins of Innomas Clinical Research, Leslie Sam…
Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as…
Speaking exclusively to PharmaBoardroom, Medicines for Africa’s Lenias Hwenda gives a comprehensive overview of the African Medicines Agency, why such a regulatory body was needed, how it differs from the…
Lenias Hwenda of Medicines for Africa examines the true impact of access to medicine initiatives in Africa, noting that many of the measures takes are often cosmetic and leave a…
Some of the top pharma news coming out of South Africa including Afrigen’s partnership with US National Institutes of Health (NIH), BioNTech’s efforts to bring an mRNA start-to-finish vaccine manufacturing network…
See our Cookie Privacy Policy Here
